RICHARD B NIMBERG DMD
Dentist in Sharon, MA
License number
Massachusetts DEN01602
Issued Date
Jan 1, 1973
Expiration Date
Jan 1, 1992
Category
Dental
Type
Dentist
Address
Address
Sharon, MA
Professional information
Methods For Inducing General And Localized Bone Apposition In-Vivo
US Patent:
4816437, Mar 28, 1989
Filed:
Jun 1, 1987
Appl. No.:
7/056023
Inventors:
Richard B. Nimberg - Sharon MA
Craig Colclasure - Watertown MA
Weldon S. Lloyd - Sharon MA
Craig Colclasure - Watertown MA
Weldon S. Lloyd - Sharon MA
Assignee:
Trustees of Boston University - Boston MA
International Classification:
C07C 800, A61K 3702
US Classification:
514 8
Abstract:
The present invention provides unique methodologies for inducing new bone apposition in-vivo generally or at a localized site and for therapeutically treating a subject afflicted with a pathological disorder of bone which is characterized by a deficiency of calcium ions in the bone matrix. The methodology for treating generalized defective skeletile mineralization comprises administering sufficient quantities of. alpha. sub. 2 HS-glycoprotein to the subject such that the concentration of this naturally occurring plasma protein is not substantially less than about 600 micrograms per milliliter of serum in-vivo. Alternatively, the method for treatment of localized defective skeletile mineralization comprises administration of a therapeutic admixture containing about 300 mircograms of. alpha. sub. 2 HS-glycoprotein per gram of filler material to the site of skeletal defect.
Immunosuppressive Polypeptides
US Patent:
4925920, May 15, 1990
Filed:
May 29, 1987
Appl. No.:
7/055296
Inventors:
John A. Mannick - Weston MA
Mary Rodrick - Beverly MA
Richard Nimberg - Sharon MA
Mary Rodrick - Beverly MA
Richard Nimberg - Sharon MA
Assignee:
Brigham and Women's Hospital - Boston MA
International Classification:
A61K 3514, C07C10352
US Classification:
530387
Abstract:
Immunosuppressive polypeptide (ISP) in substantially pure form is disclosed. Monoclonal antibodies to ISP are also described. Treatment of immune dysfunctions with ISP in substantially pure form and anti-ISP antibodies is also disclosed.